Ureas

Biotin Water® Hair, Skin, & Nails Makes Its Way To Publix Supermarkets

Friday, June 11, 2021 - 1:44pm

ROME, Ga., June 11, 2021 /PRNewswire/ --2T Water, LLC, the maker of Biotin Water Hair, Skin, and Nails announced today that Biotin Water will be sold at Publix Supermarkets across the southeast region of the United States starting June 2021.

Key Points: 
  • ROME, Ga., June 11, 2021 /PRNewswire/ --2T Water, LLC, the maker of Biotin Water Hair, Skin, and Nails announced today that Biotin Water will be sold at Publix Supermarkets across the southeast region of the United States starting June 2021.
  • 2T Water, LLC owns the exclusive rights to distribute Biotin Water Hair, Skin, and Nails which is the first biotin infused beverage that delivers 300 mcg per 16oz with zinc and folic acid included in the proprietary formula.
  • Biotin Water Hair, Skin, and Nails is formulated to ensure the body is properly hydrated while enjoying the many benefits of B7, often considered the most overlooked vitamin.
  • This new introduction of Biotin Water gives consumers more locations throughout the southeast to purchase Biotin Water in a great grocery chain.

Acadia Pharmaceuticals, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm

Tuesday, June 8, 2021 - 1:00pm

Investors are encouraged to contact attorney Lesley F. Portnoy , to determine eligibility to participate in this action, by phone 310-692-8883 or email , or click here to join the case.

Key Points: 
  • Investors are encouraged to contact attorney Lesley F. Portnoy , to determine eligibility to participate in this action, by phone 310-692-8883 or email , or click here to join the case.
  • The complaint alleges that Acadia misrepresented facts concerning their supplemental new drug application for NUPLAZID (pimavanserin), which treats dementia-related psychosis.
  • Thereafter, Acadia repeatedly stated the FDA had not identified any potential review issues, reiterating the efficacy of the drug.
  • The Portnoy Law Firm represents investors in pursuing arising from corporate wrongdoing.

New Long-Term Efficacy and Safety Analyses Evaluating RINVOQ® (upadacitinib) in Patients with Rheumatoid Arthritis to be Presented at EULAR 2021 Virtual Congress

Wednesday, June 2, 2021 - 12:00pm

The integrated safety analysis included pooled data from six randomized, controlled RINVOQ rheumatoid arthritis clinical trials.

Key Points: 
  • The integrated safety analysis included pooled data from six randomized, controlled RINVOQ rheumatoid arthritis clinical trials.
  • Long-Term Safety and Efficacy of Upadacitinib or Adalimumab in Patients with Rheumatoid Arthritis: Results at 3 years From the SELECT-COMPARE Study.
  • Integrated Safety Profile of Upadacitinib With up to 4.5 Years of Exposure in Patients With Rheumatoid Arthritis (RA Integrated Safety Update).
  • Long-Term Safety and Effectiveness of Upadacitinib or Adalimumab in Patients with Rheumatoid Arthritis: Results at 72 weeks from the SELECT-COMPARE Study.

Global Zilpaterol (CAS 119520-05-7) Market Research Report 2021 - Key Downstream Industry Trends - ResearchAndMarkets.com

Friday, May 21, 2021 - 4:13pm

b'The "Zilpaterol (CAS 119520-05-7) Global Market Research Report 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThis global report is a result of industry experts\' diligent work on researching the world market of Zilpaterol.

Key Points: 
  • b'The "Zilpaterol (CAS 119520-05-7) Global Market Research Report 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThis global report is a result of industry experts\' diligent work on researching the world market of Zilpaterol.
  • The report helps to build up a clear view of the market trends and development, identify major players in the industry, and estimate main downstream sectors.\nThe Zilpaterol global market report key points:\n'

AVEO Oncology Announces Presentation of Long-Term Efficacy Follow Up, Additional Tolerability Data from the Phase 3 TIVO-3 Study of FOTIVDA® (tivozanib) in Relapsed or Refractory Renal Cell Carcinoma

Wednesday, May 19, 2021 - 10:02pm

\xe2\x80\x9cWe were also pleased to see efficacy advantages relative to sorafenib were maintained or improved with longer follow-up.

Key Points: 
  • \xe2\x80\x9cWe were also pleased to see efficacy advantages relative to sorafenib were maintained or improved with longer follow-up.
  • Additional analyses and long-term follow up results from the TIVO-3 study to be presented at the 2021 ASCO Annual Meeting include:\nDurability of Response and Updated Overall Survival.
  • It is a potent, selective inhibitor of VEGFRs 1, 2, and 3 with a long half-life designed to improve efficacy and tolerability.
  • While AVEO may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Acadia Pharmaceuticals Inc. (ACAD)

Friday, April 30, 2021 - 5:30pm

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at shareholders@glancylaw.com to learn more about your rights.\nAcadia is a biopharmaceutical company that develops a drug called pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia, as well as an adjunctive treatment for major depressive disorder.

Key Points: 
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at shareholders@glancylaw.com to learn more about your rights.\nAcadia is a biopharmaceutical company that develops a drug called pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia, as well as an adjunctive treatment for major depressive disorder.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com , or visit our website at www.glancylaw.com .
  • If you inquire by email please include your mailing address, telephone number and number of shares purchased.\nThis press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210430005458/en/\n'

SHAREHOLDER ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Friday, April 23, 2021 - 2:20pm

If you choose to take no action, you can remain an absent class member.\nAccording to the Complaint, the Company made false and misleading statements to the market.

Key Points: 
  • If you choose to take no action, you can remain an absent class member.\nAccording to the Complaint, the Company made false and misleading statements to the market.
  • Acadia submitted an sNDA for pimavanserin to the FDA that suffered from design and statistical problems.
  • The pimavanserin sNDA did not contain the support for its approval despite the Company telling investors that it did.
  • Based on these facts, the Company\xe2\x80\x99s public statements were false and materially misleading throughout the class period.

SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Thursday, April 22, 2021 - 8:43pm

If you choose to take no action, you can remain an absent class member.\nAccording to the Complaint, the Company made false and misleading statements to the market.

Key Points: 
  • If you choose to take no action, you can remain an absent class member.\nAccording to the Complaint, the Company made false and misleading statements to the market.
  • Acadia submitted an sNDA for pimavanserin to the FDA that suffered from design and statistical problems.
  • The pimavanserin sNDA did not contain the support for its approval despite the Company telling investors that it did.
  • Based on these facts, the Company\xe2\x80\x99s public statements were false and materially misleading throughout the class period.

Arcus Biosciences Presents Updated Data for Etrumadenant in Third-Line Metastatic Colorectal Cancer and New Data on its HIF-2α Program at the AACR 2021 Annual Meeting

Saturday, April 10, 2021 - 1:33pm

Efficacy Results (n=22 efficacy-evaluable 3L+ patients as of the DCO of Feb. 26, 2021)

Key Points: 
  • Efficacy Results (n=22 efficacy-evaluable 3L+ patients as of the DCO of Feb. 26, 2021)
    Median progression-free survival (PFS) of 4.2 months.
  • Reported data for current standard-of-care (SOC) therapies have shown a median PFS of 2.0 and 1.9 months for trifluridine-tipiracil and regorafenib, respectively3,4.
  • Reported data for trifluridine-tipiracil and regorafenib have shown a median OS of 7.1 and 6.4 months, respectively3,4.
  • Few options exist today to treat third-line colorectal cancer, and these therapies are associated with significant toxicity and limited efficacy.

Lenvima (Lenvatinib) Approved for Additional Indication of Unresectable Thymic Carcinoma in Japan

Tuesday, March 23, 2021 - 9:34am

TOKYO, Mar 23, 2021 - (JCN Newswire) - Eisai Co., Ltd. and MSD K.K., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A., announced today that LENVIMA (generic name: lenvatinib mesylate), the multiple receptor tyrosine kinase inhibitor discovered by Eisai, has been approved in Japan for the additional indication of treatment of unresectable thymic carcinoma.

Key Points: 
  • TOKYO, Mar 23, 2021 - (JCN Newswire) - Eisai Co., Ltd. and MSD K.K., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A., announced today that LENVIMA (generic name: lenvatinib mesylate), the multiple receptor tyrosine kinase inhibitor discovered by Eisai, has been approved in Japan for the additional indication of treatment of unresectable thymic carcinoma.
  • This marks the first approval for LENVIMA for unresectable thymic carcinoma in Japan.
  • For unresectable thymic carcinoma, platinum-based first-line therapy is recommended.
  • In June 2020, LENVIMA received orphan drug designation in Japan for unresectable thymic carcinoma.